Document is current
Any future updates will be listed below
-
Authors
Fernández Calvo, Ovidio https://orcid.org/0000-0001-5283-9754
Muñoz Iglesias, José https://orcid.org/0000-0002-9197-0867
Abou Jokh Casas, Estephany https://orcid.org/0000-0003-0193-828X
Molina-Díaz, Aura
Anido Herranz, Urbano https://orcid.org/0000-0003-0376-5642
Casas Nebra, Javier https://orcid.org/0000-0002-9346-0799
García-Bernardo, Lucía https://orcid.org/0009-0004-4970-5068
Martínez-Breijo, Sara https://orcid.org/0000-0001-9737-1171
Lázaro-Quintela, Martín https://orcid.org/0000-0002-0657-4713
Muñiz-García, Gloria https://orcid.org/0009-0009-0614-4260
Vázquez-Estevez, Sergio https://orcid.org/0000-0002-2203-0791
- License Information
-
More Information
Article History
Received: 2 May 2024
Accepted: 7 August 2024
First Online: 12 September 2024
Change Date: 30 September 2024
Change Type: Update
Change Details: The original online version of this article was revised to correct the family names of few co-authors.
Declarations
:
: The authors declared no conflicts of interest except for: Urbano Anido Herranz declared his participation as a consultant and/or advisory role with Advanced Accelerator Applications, Astellas, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Ipsen, Merck-Pfizer and Merck Sharp and Dohme; and travel support from Bayer, GSK, Ipsen Merck-Pfizer, and Roche; and grants or honoraria from Advanced Accelerator Applications, Astra-Zeneca, Bristol-Myers Squibb, Eisai, Grünenthal, GSK (an immediate family member), Ipsen, Leo Pharma (an immediate family member), Kyowa-Kirin, Merck, Pharm, and Rovi; and his participation in clinical trials: Advanced Accelerator Applications, Astra-Zeneca, Astellas, Bayer, Bristol-Myers Squibb, Clovis, Exeltis, Ipsen, ITM,, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and Roche. Ovidio Fernández Calvo declared his participation as consultant and/or advisory role with Astellas, Bristol-Myers Squibb, Eisai, Merck, and Pfizer; and speaking honoraria from Astellas, Bayer Bristol-Myers Squibb, Ipsen, Novartis and Roche; and travel support from Astellas, Bristol-Myers Squibb and Ipsen. Martín Lázaro-Quintela declared his participation as speaker, consultant, and/or advisory role with Astellas, Astra-Zéneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Ipsen, Janssen, Lilly, Merck Sharp and Dohme, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi and Takeda; and grants or travel support from Astellas, Ipsen, Janssen, Merck Sharp and Dohme, Pierre-Fabré, Pfizer and Roche. Jose Muñoz Iglesias declared his participation as speaker, consultant, and/or advisory role and travel support from Astellas, Bayer, Janssen, Novartis, Takeda, and Roche.
: The analysis in this article does not involve any new studies of human or animal subjects performed by any of the authors.
: Since the present consensus did not involve the participation of patients, informed consent was not deemed necessary.
